IN8bio, Inc.

IN8bio, Inc. is a clinical-stage biotechnology company specializing in the development and commercialization of gamma-delta T cell therapies for cancer treatment. Its lead product, INB-200, is a genetically modified autologous gamma-delta T cell product candidate in Phase I clinical trial for glioblastoma and solid tumors. Additionally, the company is developing INB-100, an allogeneic product candidate in Phase I clinical trial for acute leukemia patients undergoing hematopoietic stem cell transplantation, as well as preclinical phase products, INB-400 and INB-300, for various solid tumor cancers.

Products

• INB-200 (Phase I clinical trial)

• INB-100 (Phase I clinical trial)

• INB-400 (preclinical phase)

• INB-300 (preclinical phase)